What’s on the horizon for higher-risk MDS? An update on emerging novel agents?

Sdílet
Vložit
  • čas přidán 19. 02. 2023
  • Dr David Sallman reviews recent advances in the management of HR-MDS, including the mode of action and latest clinical data for emerging treatments.
    Watch now: touchoncologyime.org/hr-mds-e...
    --------
    This activity is funded by an independent medical education grant from Gilead Sciences, Inc. and is jointly provided by USF Health and touchIME.

Komentáře • 1

  • @SR-zh9kp
    @SR-zh9kp Před 8 měsíci

    DR. Sallman speaks too quickly! It was disturbing to listen to him.